Current disease status-First occurrence of the cancer Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the cancer Posts on Medivizor

Irinotecan combined with capecitabine-based chemoradiotherapy before surgery improves the outcomes of patients with rectal cancer

Irinotecan combined with capecitabine-based chemoradiotherapy before surgery improves the outcomes of patients with rectal cancer

Posted by on Nov 29, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of treatment with irinotecan (Camptosar) combined with capecitabine (Xeloda) chemotherapy (ICC) before rectal cancer surgery. Researchers suggested that this combined therapy significantly improved the treatment outcomes in these patients. Some background Rectal cancer is a common...

Read More

Searching for patients with triple-negative breast cancer to test an immunotherapy combination

Searching for patients with triple-negative breast cancer to test an immunotherapy combination

Posted by on Nov 22, 2020 in Breast cancer | 0 comments

In a nutshell This study will investigate the safety and effectiveness of tiragolumab combined with atezolizumab (Tecentriq) and chemotherapy to treat triple-negative breast cancer (TNBC).  The main outcome will be the occurrence of side effects and the objective response rate (ORR).  The details Breast cancer (BC) is the most...

Read More

Evaluating sexual function in men treated with rectal cancer surgery

Evaluating sexual function in men treated with rectal cancer surgery

Posted by on Nov 20, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the long-term changes in sexual function (SF) in men after rectal cancer surgery. Researchers suggested that SF was not significantly affected by rectal cancer surgery. Some background Colorectal cancer is the third most common cancer worldwide. Of these, around 30% are rectal cancers. Newer cancer therapies...

Read More

Can tumor DNA in the blood predict how well patients with melanoma will respond to immune therapy?

Can tumor DNA in the blood predict how well patients with melanoma will respond to immune therapy?

Posted by on Nov 13, 2020 in Melanoma | 0 comments

In a nutshell This study looked at the role of circulating tumor DNA (ctDNA) in predicting treatment response in advanced melanoma. They found that in patients treated for the first time with immune treatment, patients with low ctDNA levels had a longer survival without cancer worsening. Some background Advanced melanoma describes melanoma...

Read More

Effectiveness and safety of atezolizumab compared to platinum-based chemotherapy in the treatment of advanced NSCLC

Effectiveness and safety of atezolizumab compared to platinum-based chemotherapy in the treatment of advanced NSCLC

Posted by on Nov 7, 2020 in Lung cancer | 0 comments

In a nutshell This study looked at the safety and effectiveness of atezolizumab (Tecentriq) compared to platinum-based chemotherapy for the treatment of advanced lung cancer. They found that atezolizumab improved survival compared to chemotherapy in these patients. Some background Lung cancer is classified based on how the tumor cells look...

Read More

Evaluating osimertinib for EGFR positive non-small-cell lung cancer that was surgically removed.

Evaluating osimertinib for EGFR positive non-small-cell lung cancer that was surgically removed.

Posted by on Oct 30, 2020 in Lung cancer | 0 comments

In a nutshell This trial was carried out to assess the effectiveness and safety of osimertinib (Tagrisso) after surgery for EGFR-positive advanced non-small cell lung cancer (NSCLC). The trial found that this treatment improved the outcomes of patients with stage IB to IIIA EGFR-positive NSCLC that was surgically removed. Some...

Read More

The importance of timing of radiotherapy after radical prostatectomy in patients with prostate cancer

The importance of timing of radiotherapy after radical prostatectomy in patients with prostate cancer

Posted by on Oct 29, 2020 in Prostate cancer | 0 comments

In a nutshell The study compared outcomes of adjuvant radiotherapy (AR) versus observation with salvage radiotherapy (SR) in patients with prostate cancer (PCa) after radical prostatectomy (RP). The authors found that careful observation with SR is a safer treatment after RP for preventing cancer progression. Some background RP surgically removes the...

Read More

Looking to recruit patients with prostate cancer that has spread to the bone to trial a radiation treatment.

Looking to recruit patients with prostate cancer that has spread to the bone to trial a radiation treatment.

Posted by on Oct 11, 2020 in Prostate cancer | 0 comments

In a nutshell This study is looking to recruit patients with prostate cancer (PC) spread to the bone to trial internal and external radiotherapy. The main outcome that will be measured is the length of time until patients need androgen deprivation therapy (ADT). This trial will be carried out in Utah, the United States.  The details PC...

Read More

A look at high intensity focused ultrasound removal of prostate gland: effects and complications

A look at high intensity focused ultrasound removal of prostate gland: effects and complications

Posted by on Oct 4, 2020 in Prostate cancer | 0 comments

In a nutshell This study investigated the short-term functional measures and complications for high-intensity focused ultrasound (HIFU) treatment in half of the prostate gland (hemi-gland) for patients with prostate cancer (PCa). The study showed that hemi-gland HIFU is a low-risk surgery and provides maintenance of sexual and urinary...

Read More

Does the addition of human endostatin to chemotherapy before surgery benefit patients with stage III breast cancer?

Does the addition of human endostatin to chemotherapy before surgery benefit patients with stage III breast cancer?

Posted by on Sep 29, 2020 in Breast cancer | 0 comments

In a nutshell This trial was carried out to examine the use of recombinant human (rh) endostatin (EN) with CT before surgery in patients with breast cancer (BC). The authors concluded that the addition of EN to CT significantly improved the response rate to therapy and survival in these patients. Some background BC is the most common form of...

Read More

Comparing the effects of brigatinib versus crizotinib in patients with non-small cell lung carcinoma

Comparing the effects of brigatinib versus crizotinib in patients with non-small cell lung carcinoma

Posted by on Aug 30, 2020 in Lung cancer | 0 comments

In a nutshell The study evaluated outcomes of brigatinib (Alunbrig) versus crizotinib (Xalkori) in patients with non-small cell lung carcinoma (NSCLC) and anaplastic lymphoma kinase (ALK) mutations, who were previously not treated with ALK inhibitors (ALKI). The main finding was that brigatinib had better long-term outcomes compared to crizotinib in such...

Read More

Differential effects of docetaxel-based chemotherapy according to body mass in patients with early breast cancer

Differential effects of docetaxel-based chemotherapy according to body mass in patients with early breast cancer

Posted by on Aug 9, 2020 in Breast cancer | 0 comments

In a nutshell The study investigated whether chemotherapy after surgery with or without docetaxel (Taxotere) has different outcomes in patients with different body mass indexes (BMI; a measurement of body weight in relation to height) and early breast cancer (BC). The main finding was that patients responded differently to docetaxel based on...

Read More